铂类化疗对未手术晚期卵巢癌患者的生存获益:全国性研究
该研究基于荷兰癌症登记处2018-2022年未行减瘤手术的卵巢癌患者数据,评估化疗与生存的关联。共纳入1780例患者,57.2%接受铂类化疗。启动化疗者中位总生存为11.1个月,未化疗者为1.8个月;多变量分析显示化疗与更长生存相关(时间比4.10)。继续化疗超过3个周期者生存亦显著优于停止者。结论支持未手术患者继续铂类化疗至多6个周期。
要点
- 未手术卵巢癌患者启动铂类化疗与显著更长生存相关。
- 化疗超过3个周期者中位总生存优于3周期后停止者。
- 支持未手术患者继续铂类化疗至多6个周期。
核心结论
- 在未行减瘤手术的卵巢癌患者中,铂类化疗与更长的总生存相关,且继续化疗超过3个周期与额外生存获益相关。
研究设计与样本
- 基于荷兰癌症登记处的全国性回顾性队列研究,纳入2018-2022年诊断且未手术治疗的卵巢癌患者共1780例。
主要发现
- 57.2%(N=1018)患者接受铂类化疗;启动化疗者中位总生存11.1个月(95% CI: 10.48-12.16),未化疗者1.8个月(95% CI: 1.74-2.07),p < 0.0001。
- 多变量分析中化疗与更长生存相关(时间比:4.10,95% CI: 3.35-5.01,p < 0.0001)。
- 启动化疗者中70.5%(N=691)接受至少3个周期,47.9%(N=469)接受6个周期。
- 3个周期后停止者中位总生存9.9个月(95% CI: 8.1-12.4),继续化疗者17.4个月(95% CI: 16.0-19.1),p < 0.001;继续化疗与更长生存相关(时间比:1.58,95% CI: 1.24-2.01,p < 0.001)。
关键数值与推荐
- 未手术卵巢癌患者接受铂类化疗(时间比4.10)及继续化疗超过3个周期(时间比1.58)均与更长总生存相关。
- 启动化疗者中仅47.9%完成6个周期,继续化疗至多6个周期与生存改善相关。
临床怎么用
- 对于不适合或未行减瘤手术的晚期卵巢癌患者,应启动铂类化疗并尽量坚持完成至多6个周期以改善生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with ovarian cancer who do not undergo surgery are underreported in literature. This study evaluated the impact of chemotherapy on survival in ovarian cancer patients who did not undergo cytoreductive surgery. Survival was compared between those who initiated chemotherapy and those who did not, and between patients who continued beyond three cycles and those who discontinued, adjusting for patient characteristics. METHODS: All patients diagnosed with ovarian cancer between 2018 and 2022 and not surgically treated were identified from the Netherlands Cancer Registry. Kaplan-Meier and Accelerated Failure Time models were used to evaluate the association between chemotherapy and survival. RESULTS: In total, 1780 patients who did not undergo cytoreductive surgery were included, 57.2% (N = 1018) were treated with platinum-based chemotherapy. Median overall survival in patients who initiated chemotherapy was 11.1 months (95% CI: 10.48-12.16) versus 1.8 months (95% CI: 1.74-2.07) in patients who did not (p < 0.0001). In multivariable analysis, chemotherapy was associated with longer survival (Time Ratio: 4.10, 95% CI: 3.35-5.01, p < 0.0001). Of patients who started chemotherapy, 70.5% (N = 691) received at least three cycles, and 47.9% (N = 469) received six cycles. Median overall survival in patients who stopped after three cycles was 9.9 months (95% CI: 8.1-12.4) versus 17.4 months (95% CI: 16.0-19.1) in patients who continued (p < 0.001). Continuation beyond three cycles was associated with longer survival (Time Ratio: 1.58, 95% CI: 1.24-2.01, p < 0.001). CONCLUSION: These findings support continuing platinum-based chemotherapy for up to six cycles in patients who do not undergo surgery, as this is associated with improved overall survival.
引用
- Garkhail P, de Bruin PC, Boere IA, et al. Survival benefit of platinum-based chemotherapy in non-surgically treated advanced ovarian cancer: A nationwide study. Gynecol Oncol. 2026. PMID: 41679114. doi:10.1016/j.ygyno.2026.01.772
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。